Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT03576443 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT03576443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2017
Completion date
September 30, 2021
Enrollment
36 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma